Recordati acquires EUSA Pharma UK Ltd
EMA validate filing of AT GAA for Pompe disease.
Advent bid to acquire SOBI fails.
FDA accepts for priority review sBLA for Reblozyl in adults with non-transfusion dependent (NTD) beta thalassemia. BMS + Merck Inc.,
MPA approval in China of Sylvant for Idiopathic Multicentric Castleman Disease. BeiGene + EUSA Pharma
FDA approves Keytruda as adjuvant treatment for adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.- Merck Inc.
FDA approves Cytalux for patients with ovarian cancer to identify malignant lesions .- On Target Laboratories Inc.
Bamlanivimab with etesevimab is FDA authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12.- Eli Lilly
FDA accepts for priority review the supplemental biologics license application for Vaxneuvance (pneumococcal 15-valent conjugate vaccine) for use in infants and children.- Merck Inc.
FDA issues a Complete Response Letter for plinabulin for prevention of chemotherapy-induced neutropenia.-BeyondSpring
Phase II ATTRACT-22 study shows benefits for lung injury with C 21 in COVID-19.- Vicore Pharma
Preclinical data demonstrate Xevudy (sotrovimab) retains activity against key Omicron mutations, new SARS-CoV-2 variant. GlaxoSmithKline
Sanofi to acquire Origimm Biotechnology and with it novel therapeutic vaccine ORI-001 for acne vulgaris.
Phase III open-label SHORELINE Study of SAGE 217 shows no new findings in major depressive disorder.
MHRA (UK) grants conditional marketing authorisation for COVID-19 treatment Xevudy.
Omeros sells Omidria ophthalmic franchise to Rayner Surgical.
FDA expands approval of Kyprolis to include combination with Darzalex Faspro and dexamethasone.
Publication of results from pivotal phase III study, PROTECT, of VBI’s prophylactic 3-antigen hepatitis B vaccine candidate.
The phase III DISCREET trial of Otezla achieves meaningful improvements in moderate to severe genital psoriasis and moderate to severe plaque psoriasis.
Deciphera Pharmaceuticals announces restructuring to prioritize clinical development programs and streamline commercial operations.
Adamis Pharmaceuticals updates comparative pharmacology model data supporting the higher 5 mg intramuscular dose of naloxone in Zimhi.
Merck Inc.,and Ridgeback statement on positive FDA Advisory Committee vote for investigational oral antiviral molnupiravir.
Completion of enrolment in DISSOLVE phase III study evaluating SEL 212 for chronic refractory gout.
EMA validates filing of Tab-cel for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
CTI BioPharma announces extension of FDA review period for pacritinib in myelofibrosis with severe thrombocytopenia.
Pivotal SORAYA trial of IMGN 853 shows efficacy in ovarian cancer.
Artesunate Amivas granted EU approval for treatment of severe malaria.
From soft-tissue to bone: Clinical presentation of fibrodysplasia ossificans progressiva (FOP)
Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases
Clinical value beyond price alone: anti-TNF biosimilars enable early treatment
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project
Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease
Targeted therapies in triple negative breast cancer
Targeted therapies in HER2 negative breast cancer
Targeted therapies in HER2 positive breast cancer
Breast Cancer- Targeted therapies
World Congress of Dermatology 2019 - A new ERA for global Dermatology
Opioids - Over the horizon
Opioids: The war on drugs
Opioids: the future and challenging the epidemic
Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups
Replacement therapies for opioid drugs in pain treatment
Microbiomes: is there nothing that they can't do?
Shaken not stirred your bacteriophage cocktail
From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)
Part Four | Obesity, Type 2 diabetes and cardiovascular disease: Finding the magic bullet
Part Three | Next generation obesity therapies
Part two | New hopes for treatment in the global obesity epidemic
Part One | The effects of obesity and the links to diabetes and cardiovascular disease: now and in the future
Key findings from the SWIPE study
COPD experts tackle key topics in our latest Q&A
Your guide to IBD novel treatments and assessment tools
Immobility and sleep disruption in the ICU - Latest recommendations
UPDATE: Urticaria e-learning new modules & symposia highlights
Unravelling the microbiome - health through happy communities
Psoriasis Knowledge Centre relaunches on Medthority.com
Atopic Dermatitis Knowledge Centre launched on Medthority.com
Reformulation of postnatal haemorrhage prophylaxis could save thousands in lower income countries
Medical cannabis - a novel approach to pain control
Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com
New inflammatory bowel disease (IBD) Knowledge Centre
New rare disease platform launched for Hunter Syndrome
New publication digest and infographic for Cardiologists.
Genetic variation and drug efficacy - could this pave the way for personalised medicines?
Neue Informationsmaterialien in deutscher Sprache zum Management von Schmerzen, Agitation und Delir auf der Intensivstation (in Zusammenarbeit mit Orion Pharma)
New: Symposium videos & presentations for immunologists, dermatologists and allergists
Magnetic nanoparticles could help rejuvenate damaged hearts
New findings may pave the way for novel HIV drugs
Adoptive T cell therapy, advanced melanoma and survival
Appetite and the brain - white matter integrity to blame?
Vitamin D in pregnancy - is it any good?
How close are we to a disease-modifying treatment for Alzheimer’s?
Japan's aging population and Alzheimer's
Focus on Primary Care - helping GPs diagnose, manage and treat urticaria
Prof Vincent interview - Defining the eCASH Concept in PAD Management
Inactivity in the elderly increases their cardiovascular risk by 14%
Close social relationships may slow cognitive decline
Type 2 diabetes risk may be increased by statin use in susceptible individuals
Improving non-alcoholic steatohepatitis care – is the finishing line in sight?
Acute myeloid leukaemia: Hope for new treatments
Left ventricular assist devices – A viable therapeutic option for heart failure?
Antibody-drug conjugates (ADCs)
Cancer immunotherapies
Horizons: a series of opinion & insight articles on disruptive healthcare in practice
The way ahead for cystic fibrosis
Schizophrenia: challenges in a crowded market
Nonalcoholic steatohepatitis: the next global epidemic?
Launch of LAL-Deficiency Knowledge Centre
Latest updates to the Chronic Spontaneous Urticaria Knowledge Centre
Launch of Oral Anticoagulation Reversal Knowledge Centre
SGLT2 Inhibitors: good news for diabetes
Will Glucagon-like peptide-1 agonists dominate the Type 2 Diabetes market?
Launch of Chronic Spontaneous Urticaria CME activity
Launch of new Cystic Fibrosis Knowledge Centre
Launch of new Chronic Lymphocytic Leukaemia CME
Launch of updated Hypogonadism Knowledge Centre
New approaches to anticoagulant therapy
ESOT 2015 speaker slides added to AIKN-IFI
New type 2 diabetes CME activity now available on Medthority.com
ATS 2015 symposium materials added to COPD Knowledge Centre
WCD 2015 videos added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre
Case studies added to Chronic Spontaneous Urticaria (CSU) Knowledge Centre
New hyperammonaemia resource developed for Medthority.com users
Chronic myelogenous leukaemia: a remarkable success story
Bedwetting resource receives a mobile-friendly transformation
IL-17A treatment section added to Psoriasis Knowledge Centre
Free haemato-oncology report added to AIKN-IFI congresses section
Parkinson's disease: the struggle to control symptoms
Metastatic melanoma: the new immunotherapies
